ArticleBMC ophthalmology2020
Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate.
Article in BMC ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Vitreoretinal Lymphoma: a clinical case highlighting the diagnostic and therapeutic challenge and the need for a multidisciplinary management.Annals of hematology · 2026Article
- Ocular Imaging in Intraocular Lymphoma: A Review.Clinical & experimental ophthalmology · 2026Review
- Optical coherence tomography features and visual prognosis in vitreoretinal lymphoma: a structured phenotyping study.Frontiers in medicine · 2026Article
- Orelabrutinib in combination with pomalidomide for the successful treatment of primary vitreoretinal lymphoma: a case report.Frontiers in medicine · 2026Article
- SS-OCT/OCTA Assessment of Choroidal Structure in Vitreoretinal Lymphoma Patients and Their Changes During Intravitreal Methotrexate Chemotherapy.Translational vision science & technology · 2025Article
- Primary vitreoretinal lymphoma: diagnosis, treatment, and prognosis-a review of current knowledge and future directions.Blood science (Baltimore, Md.) · 2025Review
- Clinical guidelines for the diagnosis and treatment of vitreoretinal lymphoma in Chinese patients (2024).Eye and vision (London, England) · 2025Review
- Intraocular Lymphoma: A Review.Journal of ophthalmic & vision research · 2025Review
- Case report: Intraretinal hyperflow microinfiltration lesions on swept-source optical coherence tomography angiography as a potential biomarker of primary vitreoretinal lymphoma.Frontiers in medicine · 2024Article
- Electroretinographic and Optical Coherence Tomographic Evaluations of Eyes with Vitreoretinal Lymphoma.Journal of clinical medicine · 2023Article
- Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.BMC ophthalmology · 2022Article
- Multimodal diagnostic imaging in primary vitreoretinal lymphoma.International journal of retina and vitreous · 2022Review
- Diagnostic Accuracy of Cell Block Preparations and Clinical Features Affecting It in Vitreoretinal Lymphoma.Journal of clinical medicine · 2022Article
- Clinical Features, Diagnosis, Management and Prognosis of Primary Intraocular Lymphoma.Frontiers in oncology · 2022Article
- Optical Coherence Tomography Benefits the Diagnosis and Follow-Up of Primary Central Nervous System Lymphoma with Intraocular Involvement.Cancer management and research · 2022Article
- Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.Frontiers in oncology · 2021Article
- Electrophysiological Monitoring of Focal and Entire Retinal Function during Treatment with Intravitreal Methotrexate for Intraocular Lymphoma.Case reports in ophthalmologyArticle
- Diagnostic and therapeutic challenges in primary vitreoretinal lymphoma: a practical clinical approach.Romanian journal of ophthalmologyReview
- A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDeveloping objective and repeatable indicators to evaluate the efficacy of PVRL treatment is important. The quantification of vitreous cells is a traditional criterion; however slight changes are difficult to ascertain. Spectral domain optical coherence tomography (SD-OCT) is objective, repeatable, and easily explained. The purpose of this study is to provide a longitudinal observation of OCT in PVRL treated with intravitreal injections of methotrexate (MTX) and to evaluate the utility of OCT in monitoring responsiveness of PVRL to treatment.
methodsThe medical records of patients with biopsy-positive PVRL attending our hospital between January 2016 and September 2017 who received intravitreal injections of MTX were included in this study. Pre- and post-treatment OCT images were reviewed independently by two researchers.
resultsOf the 24 cases reviewed, 10 patients (18 eyes) were included. SD-OCT abnormalities at the initial visit included vitreous cells (18/18), OR (outer retina) fuzzy borders (12/18), PED (pigment epithelium detachments) (9/18), subretinal hyperreflective infiltration (3/18), intraretinal infiltration (8/18), and SRF (subretinal fluid) (4/18). Post induction treatment, SRF in cases with RD (retinal detachment) was absorbed, and subretinal fibrosis appeared. Other lesions were significantly reduced. Post consolidation treatment, OR fuzzy borders, PED and SRF disappeared in 2 eyes, intraretinal infiltration disappeared in 1 eye, and other abnormalities further improved. Additionally, retinal fibrosis was observed in 3 eyes. One month post maintenance treatment, all abnormalities observed at the first visit vanished. At the last visit, OCT showed subretinal fibrosis and in 3 eyes (16.7%), the disruption of outer retina in 9 eyes (50%) and thinning of the whole layer in 4 eyes (22.2%).
conclusionsOur observations reveal that characteristic OCT features in PVRL patients can reduce gradually and finally vanish with therapy. We propose that SD-OCT may be employed to monitor the responsiveness of PVRL to treatment, which may influence decision making in the management of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.